FDA Drug Alerts
Announcement of a Risk Evaluation and Mitigation Strategy (REMS) for all extended-release/long-acting opioid analgesic drug products due to their risks of misuse, abuse, addiction, and overdose.
Extended-release and long-acting (ER/LA) opioid analgesics are approved for the management of chronic moderate-to-severe pain in the U.S., and can be safe and effective in appropriately selected patients when used as directed. However, opioid analgesics are also associated with serious risks and are at the center of a…
Important Drug Warning from Amylin
An important FDA-approved Drug Alert for Bydureon affecting Family/General Practice, Internal Medicine, Endocrinology, Nurse Practitioners, and Physician Assistants was published on August 1, 2012. This PDR® Drug Alert was delivered electronically to all Arkansas Medical Society members within these specialties who are registered with PDR® Network. To ensure…
Important Drug Warning Recently Issued
An important FDA-approved Drug Alert for BRILINTA (ticagrelor) affecting Interventional Cardiologists, Clinical Cardiologists, Emergency Medicine Physicians, Internal Medicine Physicians and Primary Care Physicians was published on July 19, 2012. This PDR® Drug Alert was delivered electronically to all Arkansas Medical Society members within these specialties who are registered…